Bender Robert & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$415K |
| 2 |
Evolus
EOLS
|
+$353K |
| 3 |
Summit Therapeutics
SMMT
|
+$223K |
| 4 |
Paychex
PAYX
|
+$207K |
| 5 |
T. Rowe Price
TROW
|
+$205K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$33.8M |
| 2 |
NVIDIA
NVDA
|
+$13M |
| 3 |
Intuitive Surgical
ISRG
|
+$6.12M |
| 4 |
lululemon athletica
LULU
|
+$5.6M |
| 5 |
Meta Platforms (Facebook)
META
|
+$4.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 44.5% |
| 2 | Consumer Discretionary | 22.13% |
| 3 | Healthcare | 17.68% |
| 4 | Communication Services | 11.92% |
| 5 | Financials | 2.55% |
Similar funds
Bender Robert & Associates's Q4 2024 Portfolio in Review
As of Q4 2024, Bender Robert & Associates held 47 positions worth $414M, down 12% from $471M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Bender Robert & Associates withdrew a net $78.1M in Q4 2024, closing 1 position and reducing 22 holdings. Its most notable exit was American Electric Power, an estimated $210K position sold in full.
By sector, the portfolio is most concentrated in Technology at 44% of assets, down from 47% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Bender Robert & Associates opened a new position in UroGen Pharma worth $370K.
- Bender Robert & Associates's largest Q4 2024 buy was UroGen Pharma: 34,701 shares worth $370K.
- Bender Robert & Associates added most to Eli Lilly in Q4 2024, an estimated $192K increase.
- Bender Robert & Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $33.8M.
- Bender Robert & Associates fully exited American Electric Power in Q4 2024, selling an estimated $210K.
- Bender Robert & Associates's ten largest holdings make up 73% of its $414M portfolio in Q4 2024.
- Bender Robert & Associates opened 8 new positions and closed 1 in Q4 2024.
- Bender Robert & Associates's portfolio value fell 12% quarter-over-quarter to $414M.
Based on Bender Robert & Associates's 13F filing for Q4 2024, filed 7 Feb 2025.